Company Overview and News
Facebook and Twitter deliver results amid concerns about fake news on their platforms, while Amazon may share more about Prime Day
FB CCV TWX MS.PRE MS.PRF CCZ PYPL AMD MS.PRG GOOG MS.PRA BIIB GM.WS.A GM.WS.B TWTR GM.WS.C CELG MS GM INTC CMCSK ABBV AMGN CELGZ CMCSA MA TWC CMG MAT V HAS MS.PRI GOOGL CCV.CL MS.PRK ABBV SBUX GM.WSB QCOM
The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter.
VRTX ECYT LOXO AAV VSTM VKTX ZGNX ENL FIXX LGNDZ RGNX IMMU BIIB CELG LGNYZ HRTX MS INCY NBIX ARWR RARE SRPT ICPT SUPN VKTXW XLRN FGEN LGNZZ LGND NVS LGNXZ PFE ENDP
The second-quarter earnings season is in full swing. So far, the earnings story has been good with positive earnings surprises on the back of strong revenue growth. Although estimated earnings growth of 21% for the second quarter is below the first-quarter level of 24.6%, the momentum is strong. As the season unfolds, we may see growth on par with the preceding quarter. This week will be a busy one with 750 companies including 175 S&P 500 members expected to report.
BIIB JNJ UBS NVS UBS.PRDCL ULSGF
Stocks were looking for direction on Monday as the weekend offered little news about trade wars and tariffs beyond what was known last week. The investing community has had less success and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for 2019 and beyond.
HON SLB EVER MS.PRE MS.PRF MS.PRG MS.PRA DLPH COP MS.PRI HON CZR BJ BIIB MS.PRK AAPL TRI SLB MS GDDY
GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has enrolled the first patient of the second cohort in the company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).
Earnings reporting season for the second quarter is now well underway. So far, things are looking good. The biotech industry has yet to see any significant earnings representation. That will change this week when at least eight large biopharma firms are scheduled to report second-quarter earnings and revenues.
AMGN CELGZ GILD BIIB ALXN CELG TRI ABBV LLY ABBV BMY
Biogen recently announced positive results from BAN2401's phase 2 trial that showed the potential to be the first disease-modifying drug on the market.
Heading into the July 4th holiday, US equities were in a bit of a funk with the S&P 500 down nearly 3% from its recent high in June. The July 4th holiday must have been just the rest the bulls needed, though, because since then, the S&P 500 has gone on to make a higher high with eight daily gains in the eleven trading days since July 4th. So, which sectors have been behind the market's recent strength? Leading the way higher has been Technology (what else is new?), which is up over 5%.
FB BIIB AVGO HEAR NFLX LB
Staging a turnaround, the biotech sector registered a rise in the past month after coping with a difficult preceding year. In the recent past, the sector witnessed some encouraging news in the form of positive data read outs on key pipeline drugs as well as favorable regulatory updates.
XLRN CELGZ BIIB CELG
Biogen Inc. (BIIB - Free Report) will report second-quarter 2018results on Jul 24, before market open. Last quarter, the company delivered a positive earnings surprise of 2.02%.
AMGN BIIB ABBV ABBV
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
BIIB JUNO JNJ MCK CELG TEVA
AbbVie, Inc. (ABBV - Free Report) has signed a non-exclusive licensing deal with Mylan (MYL - Free Report) regarding the latter’s proposed biosimilar version of AbbVie’s blockbuster arthritis drug, Humira, in the United States. Per the agreement, Mylan will have a license to launch its biosimilar Humira in the United States and in various other countries, excluding Europe, on Jul 31, 2023.
AMGN BIIB ABBV ABBV CHRS
8h - Asif
Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
Silicon Investor Message Boards
This table lists all message boards related to BIIB / Biogen Inc. on message board site Silicon Investor.
|Biogen||(BIIB) Biogen Inc.|
as of ET